| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 2.83 MB | Adobe PDF |
Orientador(es)
Resumo(s)
MASK‐air®, a validated mHealth app (Medical Device regulationClass IIa) has enabled
large observational implementation studies in over 58,000 people with allergic rhinitis
and/or asthma. It can help to address unmet patient needs in rhinitis and asthma care.
MASK‐air® is a Good Practice of DG Santé on digitally‐enabled, patient‐centred care.
Itis also a candidate Good Practice ofOECD (Organisation for EconomicCo‐operation
and Development). MASK‐air® data has enabled novel phenotype discovery and
characterisation, as well as novel insights into the management of allergic rhinitis.
MASK‐air® data show that most rhinitis patients (i) are not adherent and do notfollow
guidelines, (ii) use as‐needed treatment, (iii) do not take medication when they are
well, (iv) increase their treatment based on symptoms and (v) do not use the recom mended treatment. The data also show that control (symptoms, work productivity,
educational performance) is not always improved by medications. A combined
symptom‐medication score (ARIA‐EAACI‐CSMS) has been validated for clinical
practice and trials. The implications of the novel MASK‐air® results should lead to
change management in rhinitis and asthma.
Descrição
Palavras-chave
Asthma Digital MASK.-air mHealth Rhinitis